EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Self‐Powered α Radionuclide Nanomedicine: Mitochondria‐Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy

Xian Li, Chaochao Wang, Yelin Wu, Jiajia Zhang, Han Zhang, Shanshan Qin, Linglin Tang, Fei Yu iD

Advanced Materials · 2025

DOI: 10.1002/adma.202504612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Xian Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, P. R. China. Hauptthemen laut MEDLINE: Mitochondria, Radioimmunotherapy, Alpha Particles, Nanomedicine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Internal Radionuclide Therapy (IRT) faces significant challenges, particularly the limited controlled penetration depth of conventional β rays and the inefficient targeted delivery of α‐emitters. In this study, a mitochondria‐targeted, self‐powered α radionuclide nanomedicine, and pioneer a groundbreaking “suborganelle precise radiodynamic immunotherapy” paradigm that synergistically integrates physical irradiation, catalytic chemistry, and immunomodulation to overcome the historical limitations of IRT is developed. The innovation establishes a “radionuclide energy internal cycling” strategy through 223 RaCl 2 (the first FDA‐approved α‐emitter), unlocking three synergistic therapies from one radionuclide: precise ionizing radiation, self‐powered catalysis, and immunogenic reprogramming. This paradigm uniquely exploits the full decay spectrum (α particles, β electrons, γ photons) to synchronize physical, chemical, and biological anti‐tumor mechanisms without requiring external energy inputs, offering a transformative solution to overcome the physical‐biological barriers of IRT and bridge localized eradication with systemic immune regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaRadioimmunotherapyAlpha ParticlesNanomedicineRadioisotopesAnimalsHumansMiceCell Line, TumorNeoplasms

Stichwörter der Autor:innen

alpha therapymitochondria‐targetedradiodynamicradionuclide therapyradium‐223

Substanzen

Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, P. R. China.
  • Institute of Nuclear Medicine, Tongji University School of Medicine, Shanghai, 200072, P. R. China.
  • Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
  • Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160 Pujian Road, Shanghai, 200127, China.

ORCID-Profile: Fei Yu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, X., Wang, C., Wu, Y., Zhang, J., Zhang, H., Qin, S., Tang, L., & Yu, F. (2025). Self‐Powered α Radionuclide Nanomedicine: Mitochondria‐Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202504612

Vancouver

Li X, Wang C, Wu Y, Zhang J, Zhang H, Qin S, et al. Self‐Powered α Radionuclide Nanomedicine: Mitochondria‐Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy. Advanced Materials. 2025. doi:10.1002/adma.202504612

BibTeX
@article{Li2025,
  author = {Li, Xian and Wang, Chaochao and Wu, Yelin and Zhang, Jiajia and Zhang, Han and Qin, Shanshan and Tang, Linglin and Yu, Fei},
  title = {Self‐Powered α Radionuclide Nanomedicine: Mitochondria‐Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy},
  journal = {Advanced Materials},
  year = {2025},
  doi = {10.1002/adma.202504612}
}
Kostenlos starten →